What question did this study set out to answer?

This work aims to outline current and future management options for HER2-positive metastatic breast cancer.

Current and Future Management of HER2-Positive Metastatic Breast Cancer

View Full Paper

Ask AI

Bookmark

This work aims to outline current and future management options for HER2-positive metastatic breast cancer.
Overview of established treatment protocols, including combinations of trastuzumab and pertuzumab.
Discussion of emerging therapies for late-line treatment options.
Review of the role of biomarkers in patient selection for targeted therapies.
Standard care includes taxane, trastuzumab, and pertuzumab in first-line treatment.
Multiple new therapies are becoming available, such as tucatinib and neratinib, showing promising results.
Emerging strategies may include chemo-free approaches for hormone receptor-positive, HER2-positive breast cancer.

No takes yet. Share an insight, caveat, or question.

Overview of treatments and emerging therapies for HER2-positive advanced breast cancer, suggesting evolving strategies.

Martínez‐Sáez et al. (2021) studied this question.

View Full Paper

Ask AI

Bookmark